This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Zai Lab (ZLAB) in Focus: Stock Moves 6.2% Higher
by Zacks Equity Research
Zai Lab (ZLAB) saw a big move last session, as its shares jumped more than 6% on the day, amid huge volumes.
Increased Earnings Estimates Seen for Illumina (ILMN): Can It Move Higher?
by Zacks Equity Research
Illumina (ILMN) is seeing positive earnings estimate revisions, suggesting that it could be a solid choice for investors.
Illumina (ILMN) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Illumina (ILMN) closed at $344.76 in the latest trading session, marking a -0.17% move from the prior day.
Phibro Animal (PAHC) Q4 Earnings Beat, Sales Improve Y/Y
by Zacks Equity Research
Phibro (PAHC) witnesses year-over-year improvement across all segments in Q4.
Amgen Files for Once-Weekly Regimen for Myeloma Drug Kyprolis
by Zacks Equity Research
Amgen (AMGN) submits a supplemental new drug application to the FDA, seeking an approval for once-weekly dosage of its multiple myeloma drug, Kyprolis, combined with dexamethasone (Kd).
Nasdaq ETF Hits New Highs: 5 Stocks Up More Than 50%
by Sweta Killa
Though most of the stocks in the Nasdaq ETF portfolio delivered strong returns so far this year, a few were the real stars, having gained more than 50%.
5 Top Stocks Likely to Beat Earnings Estimates
by Sanghamitra Saha
These top-ranked stocks are likely to beat on bottom line in their next releases.
Here's Why You Should Hold On to DexCom (DXCM) Stock Now
by Zacks Equity Research
DexCom (DXCM) is expected to benefit from lucrative prospects in the diabetes market. However, the company's margins were under pressure in the last reported quarter.
Zacks.com featured highlights include: ICU Medical, FTI, Aspen, Old Dominion and Illumina
by Zacks Equity Research
Zacks.com featured highlights include: ICU Medical, FTI, Aspen, Old Dominion and Illumina
Bausch (BHC) Gets FDA Approval for Altreno for Acne Vulgaris
by Zacks.com
Bausch (BHC) advances its dermatology portfolio with the FDA approval of Altreno for acne vulgaris.
Zai Lab Stock Down, Atopic Dermatitis Candidate Trial Fails
by Zacks Equity Research
Shares of Zai Lab (ZLAB) decline following the failure of a phase IIA study on its pipeline candidate, ZL-3101, for the treatment of atopic dermatitis.
5 Momentum Stocks Worth Investing in via Driehaus Strategy
by Zacks Equity Research
Using the "buy high and sell higher" rule, Richard Herman Driehaus has created an investment approach.
Indexes Close at Record High as Markets Move North: 5 Picks
by Nalak Das
As a result of markets' northbound movement, two major indexes ??? S&P 500 and Nasdaq Composite ??? closed at an all-time high on Aug 24.
Here's Why You Should Invest in Integer (ITGR) Stock Now
by Zacks Equity Research
Integer Holdings (ITGR) gains on strong quarterly performance. The company is likely to gain from the Cardio & Vascular, Neuromodulation and Non-Medical Electrochem markets.
Veeva Systems (VEEV) Q2 Earnings & Revenues Beat Estimates
by Zacks Equity Research
Veeva Systems (VEEV) gains from its flagship Vault platform. Also, expanding margins are an added positive for the company.
AbbVie Posts Positive Data on Elagolix for Uterine Fibroids
by Zacks Equity Research
AbbVie (ABBV) reports positive top-line results from a phase III extension trial on its investigational candidate Elagolix for treating uterine fibroids in women.
Exact Sciences Inks Cologuard Co-Promotion Deal With Pfizer
by Zacks Equity Research
Exact Sciences (EXAS) reaches a co-promotion agreement with Pfizer to commercialize its non-invasive screening test for colorectal cancer, Cologuard. The stock rallies following this news.
Here's Why You Should Invest in Illumina (ILMN) Stock Now
by Zacks Equity Research
Illumina (ILMN) gains on strategic partnerships and international prospects.
Pacira (PCRX) Rides High on Robust Exparel Performance
by Zacks Equity Research
Pacira (PCRX) focuses on improving sales of its flagship product Exparel. The drug's label expansion programs also look encouraging.
Is Illumina (ILMN) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Is (ILMN) Outperforming Other Medical Stocks This Year?
Bull Market Set to Become Longest in History: 5 Picks
by Swarup Gupta
The strength of the economy and the success of U.S. tech majors indicates that the rally isn't going to run out of steam.
Myriad Genetics (MYGN) Beats on Earnings & Revenues in Q4
by Zacks Equity Research
Myriad Genetics (MYGN) witnesses strong performances from GeneSight, EndoPredict, Vectra DA and Prolaris tests in Q4.
Alexion's BLA for ALXN1210 Gets Priority Review From FDA
by Zacks Equity Research
The FDA grants priority review to Alexion's (ALXN) BLA for its C5 complement inhibitor ALXN1210 with respect to the treatment of patients with paroxysmal nocturnal hemoglobinuria.
Medtronic (MDT) Q1 Earnings Beat on Growth in All Lines
by Zacks Equity Research
All major business groups of Medtronic (MDT) contribute to solid top-line growth at CER, which highlighted sustainability across groups and regions.
Roche's Lung Cancer Drug Alecensa Gets Approval in China
by Zacks Equity Research
The China National Drug Administration approves Roche's (RHHBY) cancer drug Alecensa as a monotherapy for first-line treatment of advanced non-small cell lung cancer.